Goldman Sachs expects Nvidia ’beat and raise,’ lifts price target to $240
Director Bruce Booth indirectly sold shares of Sionna Therapeutics Inc. (NASDAQ:SION) between September 29 and October 1, 2025, according to a recent SEC Filing. The sales amounted to a total value of $2.37 million. The transactions come as the stock trades near its 52-week high of $30.61, having surged approximately 180% over the past six months, according to InvestingPro data.
The sales were executed in multiple transactions at prices ranging from $29.95 to $30.41.
Specifically, the sales included the following:
54,637 shares sold on September 29 at a weighted average price of $30.09, for a total of $1,644,037.
11,468 shares sold on September 29 at a weighted average price of $30.09, for a total of $345,072.
10,239 shares sold on September 30 at a weighted average price of $30.06, for a total of $307,704.
2,149 shares sold on September 30 at a weighted average price of $30.06, for a total of $64,608.
165 shares sold on October 1 at a price of $29.95 per share, for a total of $4,942.
35 shares sold on October 1 at a price of $29.95 per share, for a total of $1,048.
The shares were indirectly held by Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund II, L.P. Booth disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
These transactions were made pursuant to a Rule 10b5-1 trading plan. With a market capitalization of $1.3 billion, Sionna currently trades above its InvestingPro Fair Value, while analyst price targets range from $22 to $46 per share. Get access to more exclusive insights and 12 additional ProTips with InvestingPro.
In other recent news, Sionna Therapeutics has reported its second-quarter 2025 financial results, which have caught the attention of investment analysts. Guggenheim reiterated its Buy rating for the company, maintaining a price target of $45.00. This decision follows the release of positive topline data from Sionna’s Phase I trials, which showed promising safety and pharmacokinetic results. The company plans to advance its NBD1 stabilizers, SION-719 and SION-451, into further clinical development after successful testing in over 200 healthy volunteers. Additionally, Sionna Therapeutics has initiated a Phase 1 trial to evaluate its novel cystic fibrosis treatment combinations, including SION-451, SION-2222, and SION-109. This trial aims to assess the safety, tolerability, and pharmacokinetics of these combinations in healthy volunteers. In terms of analyst perspectives, RBC Capital has initiated coverage of Sionna Therapeutics with a Sector Perform rating and a $22.00 price target. Analyst Brian Abrahams from RBC Capital noted that the company’s CFTR modulators could establish Sionna as a significant player in the cystic fibrosis space over the long term.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.